At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Secretindrug
Likely dose
Secretin 1 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers
In Brief
A Phase 1 clinical trial evaluating Secretin for Chronic Pancreatitis. Completed, enrolled 12 participants across 1 site.
Detailed Summary
Alterations in pancreatic blood have been implicated in pancreatic inflammation and pain. Several modalities have been used to assess pancreatic blood flow although some of these methods are invasive, use ionising radiation or intravenous contrast media. This is the first study to utilise non-invasive magnetic resonance imaging to quantify flow within arteries supplying the pancreas and pancreatic perfusion is response to secretin stimulation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pancreatitis
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
Primary CompletionSep 2011
Study CompletionOct 2011
First PostedOct 2011
TodayJul 2026
First PostedOct 14, 2011
Enrollment StartSep 1, 2010
Primary CompletionSep 1, 2011
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 14.7 years ago
Interventions
Secretindrug
Secretin 1 IU/kg over 3 min